FIG 2.

GI TARGET report content: (A) the PDF report includes (I) patient and sample information, (II) report summary, (III) GI cancer relevant genomic features, (IV) clinical trial matches from MatchMiner, and (V) additional report information. (II) is the most important section of the report and includes the "Summary of notable findings", which is a prioritized list of action items on the basis of integrated review of OncoPanel results in the context of relevant clinicopathologic information and additional commentary from the GI TARGET team that is useful for the primary oncologist. The "Summary of discussion" includes more detailed information expanding on the above recommendations. (IV) displays all clinical trial matches from MatchMiner on the basis of tier 1-3 SNV/INDELs, tier 1-3 SVs, and CNVs regardless of whether they are found in a gene listed in GI KB1 and, in the case of SNV/INDELs and SV, regardless of the interpretation (ie, oncogenic/likely oncogenic/VUS/neutral). Tier 4 SNV/INDELs are omitted from the GI TARGET report unless they are the basis of clinical trial matches, in which case they appear in a separate table titled "Additional Trial Matches Based on Variants of Unknown Significance." (B) Example of GI TARGET summary of notable findings from a pancreatic cancer case. CNVs, copy number variants; GI TARGET, Gastrointestinal Treatment Assistance Regarding Genomic Evaluation of Tumors; KB, knowledgebase; SNV/INDELs, single nucleotide variants/insertions/deletions; SV, structural rearrangement variants; VUS, variant of unknown significance.